Since the pharmacodynamics and pharmacokinetics of a GLP-1 receptor agonist in patients with AUD have not been investigated, we chose a dosing regimen consistent with established tolerability and efficacy in treatment of type 2 diabetes, i.e., exenatide, 2 mg subcutaneously once weekly. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.